title: [Efficacy and safety of antiplatelet drugs in patients with chronic kidney disease].
abstract: The risks and benefits of antiplatelet treatment may be different in patients with chronic kidney disease, in whom tendency to thrombosis and bleeding hazards might be increased. Chronic kidney disease is also associated with poor response to antiplatelet therapy, and this represents a potentially important clinical problem in the setting of percutaneous coronary intervention and acute coronary syndrome. The use of new, potent P2Y12 inhibitors appears promising, although special consideration should be given to possible bleeding events. This review evaluates the benefits and harms of antiplatelet drugs in patients with chronic kidney disease.
authors: Department of Cardiology, Osmaniye State Hospital, Osmaniye, Turkey. ibrahimyildiz79@yahoo.com.
authors: Ibrahim
authors: I
authors: Yıldız
authors: Department of Cardiology, Kadirli State Hospital, Osmaniye, Turkey.
authors: Pınar
authors: P
authors: Özmen Yıldız
authors: Department of Cardiology, Mersin University Faculty of Medicine, Mersin, Turkey.
authors: Oben
authors: O
authors: Döven
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D051436:Renal Insufficiency, Chronic; D012449:Safety
chemical_list: D010975:Platelet Aggregation Inhibitors